Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Flint AC, Mitchell DK, Angus SP, Smith AE, Bessler W, Jiang L, Mang H, Li X, Lu Q, Rodriguez B, Sandusky GE, Masters AR, Zhang C, Dang P, Koenig J, Johnson GL, Shen W, Liu J, Aggarwal A, Donoho GP, Willard MD, Bhagwat SV, Clapp DW, Rhodes SD. Flint AC, et al. Among authors: masters ar. Clin Cancer Res. 2023 Sep 1;29(17):3438-3456. doi: 10.1158/1078-0432.CCR-22-2854. Clin Cancer Res. 2023. PMID: 37406085 Free PMC article.
Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2.
Wahle BM, Hawley ET, He Y, Smith AE, Yuan J, Masters AR, Jones DR, Gehlhausen JR, Park SJ, Conway SJ, Clapp DW, Yates CW. Wahle BM, et al. Among authors: masters ar. Oncotarget. 2017 Oct 24;9(1):718-725. doi: 10.18632/oncotarget.22002. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416648 Free PMC article.
New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types.
Gampala S, Moon HR, Wireman R, Peil J, Kiran S, Mitchell DK, Brewster K, Mang H, Masters A, Bach C, Smith-Kinnamen W, Doud EH, Rai R, Mosley AL, Quinney SK, Clapp DW, Hamdouchi C, Wikel J, Zhang C, Han B, Georgiadis MM, Kelley MR, Fishel ML. Gampala S, et al. Pharmacol Res. 2024 Mar;201:107092. doi: 10.1016/j.phrs.2024.107092. Epub 2024 Feb 2. Pharmacol Res. 2024. PMID: 38311014 Free PMC article.
In Vivo Targeting Replication Protein A for Cancer Therapy.
VanderVere-Carozza PS, Gavande NS, Jalal SI, Pollok KE, Ekinci E, Heyza J, Patrick SM, Masters A, Turchi JJ, Pawelczak KS. VanderVere-Carozza PS, et al. Front Oncol. 2022 Feb 18;12:826655. doi: 10.3389/fonc.2022.826655. eCollection 2022. Front Oncol. 2022. PMID: 35251993 Free PMC article.
Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice.
Oblak AL, Cope ZA, Quinney SK, Pandey RS, Biesdorf C, Masters AR, Onos KD, Haynes L, Keezer KJ, Meyer JA, Peters JS, Persohn SA, Bedwell AA, Eldridge K, Speedy R, Little G, Williams SP, Noarbe B, Obenaus A, Sasner M, Howell GR, Carter GW, Williams H, Lamb BT, Territo PR, Sukoff Rizzo SJ. Oblak AL, et al. Among authors: masters ar. Alzheimers Dement (N Y). 2022 Jul 14;8(1):e12317. doi: 10.1002/trc2.12317. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35846156 Free PMC article.
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Flint AC, Mitchell DK, Angus SP, Smith AE, Bessler W, Jiang L, Mang H, Li X, Lu Q, Rodriguez B, Sandusky GE, Masters AR, Zhang C, Dang P, Koenig J, Johnson GL, Shen W, Liu J, Aggarwal A, Donoho GP, Willard MD, Bhagwat SV, Clapp DW, Rhodes SD. Flint AC, et al. Among authors: masters ar. Clin Cancer Res. 2024 May 1;30(9):1992. doi: 10.1158/1078-0432.CCR-24-0635. Clin Cancer Res. 2024. PMID: 38690594 No abstract available.
36 results